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Point: There is a need for supplemental XRT with brachytherapy
in the treatment of intermediate-risk prostate
cancer patients
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Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NYOne of the critical elements that have led to improved EBRT yields a BED of approximately 230 Gy. This marked
outcomes for intermediate-risk prostate cancer patients is
the use of dose escalation (1e7). A meta-analysis of the
seven randomized dose-escalated trials has demonstrated
a biochemical control benefit for intermediate-risk patients
with increasing biologically effective doses (BEDs) (5).
Viani et al. found that a near linear benefit was evident with
escalation of the radiation dose, and there was no sign that
the dose effect had reached a plateau with further escalation
of the radiation dose; these studies included BED of up to
175 Gy. In addition, Levegrun et al. (8) have used posttreat-
ment biopsies to represent local control and suggested
a TCP50 of 70.5 Gy (BED of 155 Gy) and near linear tumor
control improvements with doses approaching 85 Gy (BED
of 187 Gy). Current therapy for intermediate-risk patients
with dose-escalated external beam radiation therapy (EBRT)
plus androgen deprivation therapy (9, 10) result in 10-year
actuarial biochemical failure rates of 20e25% and local
failure rates of 15e25% (11, 12). As seen in Table 1, most
brachytherapy implant alone series result in 10-year actu-
arial biochemical failure rates of greater than 20% for
intermediate-risk patients. Clearly, intermediate-risk pros-
tate cancer is not uniformly eradicated with BEDs of brachy-
therapy implant or dose-escalated EBRT alone (BED of
150e190 Gy) and warrants more aggressive therapy.
Supplemental EBRT is one of the most reliable and
consistent ways for safely escalating radiation dose levels
in conjunction with brachytherapy to facilitate the delivery
of higher BED levels within the prostate and the extrapro-
static tissue. Using BED models published by Stock et al.
(13) (using a/b of 2.0), 125I monotherapy implant prescrip-
tion of 144 Gy has a BED of approximately 160 Gy based
on the D90 coverage; however, combination therapy with
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improved biochemical and local control. Stone et al. (14)
reported that intermediate-risk patients had a positive post-
treatment biopsy rate of 14% when treated with a BED
!150 Gy and only 5.3% biopsy positivity for BED
O200 Gy. Importantly, residual disease post-EBRT has
been shown to predict for both distant metastases and pros-
tate cancererelated mortality (12). Furthermore, a multi-
institutional study of intermediate- and high-risk patients
demonstrated that a BEDO220 Gy resulted in significantly
improved freedom from biochemical failure, a dose not
readily achieved by brachytherapy implant alone.
Beyond intraprostatic dose escalation, another important
and recognized advantage of supplemental EBRT is the
ability to cover extraprostatic disease for extracapsular
extension (ECE), seminal vesicle invasion (SVI), and even
lymph node involvement (Table 2). Based on original Partin
data using the Roach formula, even low-risk patients can
haveO40% risk of having ECE at time of radical prostatec-
tomy (15). To complicate this issue further, standard hema-
toxylin and eosin (H & E) staining has been shown to
underestimate the presence of ECE, which has been
confirmed by molecular studies (16). Multiple series have
demonstrated that ECE commonly extends up to 5 mm
radially from the prostate, with maximum tumor extension
documented $10 mm (17, 18). Dosimetric data from
Merrick et al. (19) have demonstrated that the distance
measured radially from the prostate is encompassed by
the 100% isodose line at a distance of $3 mm from the
prostate only 86% of the time and!70% is encompassed
when at a distance $5 mm from the prostate. Even when
analyzing coverage by the 75% isodose line, ~7% of the
coverage on average was not encompassed $5 mm from
the prostate (19). At the edge of the target volume, the dose
decreases up to ~20 Gy/mm; thus, if the margin is 3 mm at
a point, but ECE extends to 5 mm, a 144-Gy implant may
decrease to 100 Gy in the region of ECE. This would repre-
sent substantial underdosage of disease and would have thehed by Elsevier Inc. All rights reserved.
Table 1
Summary of long-term biochemical control outcomes by modality
Study Modality n Dose
8-year 10-year
NotesbRFS (%) bRFS (%)
Brachytherapy alone
Hinnen et al. (26) Brachy 369 I125 was 144 Gy 61
Klein et al. (27) Brachy 204 I125 was 144 Gy 82
Munro et al. (28) Brachy 187 I125 was 145 Gy 78
Taira et al. (29) Brachy 144 I125 was 145 Gy
Pd103 was 125 Gy
96
Vassil et al. (30) Brachy 256 I125 was 144 Gy 75) )Estimated based on KM
Multi-institutional report (31) Brachy 960 I125 was 144 Gy
Pd103 was 130 Gy
61 55) )Estimated based on KM
Ho et al. (32) Brachy 383 I125 was 160 Gy
Pd103 was 124 Gy
76
Combination brachytherapy plus EBRT
Critz et al. (33) Combo-RT 447 I125 was 110 Gy
EBRTwas 45 Gy with boost of
7.5 Gy all in 1.5 Gy/fx
80 Boost to prostate base
and seminal vesicles
Dattoli et al. (34) Combo-RT 119 Pd103 was 80e90 Gy
EBRT was 39e54 Gy in
1.8 Gy/fx
87
Ho et al. (32) Combo-RT 175 Pd103 was 100 Gy
EBRT was 45 Gy in 1.8 Gy/fx
91
Merrick et al. (35) Combo-RT 425 I125 was 110 Gy
Pd103 was 90 Gy
EBRT was 45 Gy in 1.8 Gy/fx
97 80% of patients were
combo-RT
Brachytherapy as monotherapy or combination therapy: outcomes not separated by modality
Bittner et al. (36) Brachy 171 Not specified 97
Combo-RT 465 EBRT was 45 Gy in 1.8 Gy/fx
Burri et al. (37) Brachy 460 I125 was 160 Gy
Pd103 was 124 Gy
88
Combo-RT 75 Pd103 was 100 Gy
EBRT was 45 Gy in 1.8 Gy/fx
Merrick et al. (38) Brachy 212 I125 was 144 Gy
Pd103 was 125 Gy
98
Combo-RT I125 was 110 Gy
Pd103 was 90 Gy
EBRT was 45 Gy in 1.8 Gy/fx
Potters et al. (39) Brachy 445 I125 was 144 Gy
Pd103 was 136 Gy
76
Combo-RT 109 I125 was 108 Gy
Pd103 was 102 Gy
EBRT was 41.4e45 Gy in
1.8 Gy/fx
Stone et al. (14) Brachy 141 I125 was 160 Gy
Pd103 was 124 Gy
79
Combo-RT Pd103 was 100 Gy
EBRT was 45 Gy in 1.8 Gy/fx
Zelefsky et al. (40) Brachy 553 I125 was 144 Gy
Pd103 was 125 Gy
90) )Estimated based on KM
Combo-RT I125 was 110 Gy
Pd103 was 100 Gy
EBRT was 50.4 in 1.8 Gy/fx
bRFS 5 biochemical recurrence-free survival; Brachy 5 brachytherapy; KM 5 Kaplan Meier; Combo-RT 5 combination brachytherapy and external
beam radiotherapy; EBRT 5 external beam radiotherapy.
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monotherapy, a grossly insufficient dose to treat ECE. This
concern of monotherapy potentially representing underdos-
age of disease is clearly illustrated in Fig. 1.
Despite excellent clinical outcomes with combination
therapy, one must ask if we are simply shifting thetherapeutic ratio by increasing tumor control with
a concomitant increased risk for toxicity, or if we are actu-
ally improving the therapeutic ratio. Multiple prospective
trials have evaluated the safety of combination therapy.
Two randomized Phase 3 trials found slightly differing
results regarding the toxicity of combination EBRT and
Table 2
Benefits of supplemental external beam radiotherapy
Dose escalation
Intraprostatic dose escalation
Extracapsular extension #5 mm from capsule and proximal seminal
vesicles dose escalation
Improved coverage
Ability to cover extracapsular extensionO5 mm from prostate
Ability to treat entire seminal vesicles
Ability to treat pelvic lymph nodes
Compensate for an inadequate implant
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combination therapy resulted in similar rates of genitouri-
nary (GU) toxicity but, interestingly, demonstrated decreased
rates of acute rectal toxicity with combination therapy.
Sathya et al. (6) reported a nonsignificant ( p 5 0.09) in-
crease in late GU toxicity with combination therapy over
non-doseeescalated EBRT, and no difference in late GI
toxicity. Radiation Therapy Oncology Group 0019 was
a Phase II multi-institutional trial that used combination
EBRTwith low dose rate (LDR) brachytherapy and reported
that of 138 patients, 4 (2.9%) experienced Grade 3 gastroin-
testinal (GI) toxicity and 15 (8.3%) experienced Grade $3
GU toxicity (21). Notably, this trial required a four-field
box technique with margins up to 2 cm on the clinical target
volume. Utilization of intensity-modulated radiation therapy,
and even image-guided radiotherapy with fiducial marker
placement, likely would have reduced the toxicity further.
The Cancer and Leukemia Group B 99809 reported theirFig. 1. Sample dosimetric comparison of implant alone to combination
therapy. Example of dosimetric comparison of implant alone to combina-
tion therapy with EBRT and brachytherapy boost. Blue dashed line: pros-
tate contour; red solid line: 100% isodose line; green solid line: 75%
isodose line. Interval spacing between positions of 5 mm. EBRT5 exter-
nal beam radiation therapy.long-term Phase II results from combination brachytherapy
and EBRTwith the addition of androgen deprivation therapy
for intermediate-risk patients (22). With a median followup
of over 6 years, the authors reported remarkable low rates
of late Grade 3 toxicity (3% [95% confidence interval,
0e8%]). As there continue to be advances in imaging tech-
nology, there is a potential for additional improvements in
intraoperative treatment planning and delivery to further
improve outcomes.
It would be an overstatement to imply that all
intermediate-risk patients require combination therapy.
‘‘Intermediate risk’’ comprises a heterogeneous group of
patients with vastly different risks for failure (23). The
current National Comprehensive Cancer Network risk
grouping does not take into account important prognostic
features such as percent positive biopsy cores (9), primary
Gleason pattern (24), or prostate-specific antigen kinetics
(25). For this reason, favorable intermediate-risk patients
with low volume of disease and few intermediate-risk
features may have adequate tumor control with a brachy-
therapy implant alone. However, patients with bulky
disease or Gleason score 4þ 3 are at high risk of recurrence
and extraprostatic extension and warrant more aggressive
combination therapy.
Ultimately, the resolution of our point counterpoint
debate will be addressed when the results of Radiation
Therapy Oncology Group 0232 become available in the
future. In this trial composed of intermediate-risk men
treated with brachytherapy, patients are randomized to the
addition of supplemental EBRT. This trial primarily
includes favorable intermediate-risk patients and will
provide Level 1 evidence to evaluate the effect of increased
BED and improved extraprostatic coverage on tumor
control prospectively. Until these results are known, the
current data support the advantages of supplemental EBRT
for intermediate-risk patients.References
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